- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
PCOC SPOTLIGHT: Empowering Stakeholders Across the Breadth of Oncology
Joseph Alvarnas, MD, a co-chair of Patient-Centered Oncology Care® (PCOC), discussed the unique nature of PCOC and what it offers for providers, payers, policy leaders, and technology experts who take part. Alvarnas is vice president, Government Affairs; senior medical director, employer strategy, and clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope.
Who are the stakeholders who participate in PCOC?
ALVARNAS: The beauty of this meeting is that it really helps to empower stakeholders across the breadth of oncology. We’re not just talking about clinicians, we’re not just talking about leaders of health care systems, but also the other essential members: those in pharma, those who are leading by helping to develop pathways, those who are leading on the payer side by really exercising new levels of creativity in payment systems.
Part of the beauty of this meeting is that you have stakeholders who often have their own meetings and often have separate conversations, and what you fi nd not only in the panels, but also in the breaks in between when people have a chance to visit and talk and chat—whether it’s by a virtual means or an in-person means—is this great cross-pollination of ideas. There’s a general level of excitement that builds in that room as all of these diverse stakeholders, who fairly rarely engage in these kinds of conversations, go deeper and deeper into the future. The beauty of oncology is what makes it so exciting, the diversity of stakeholders, and the depth of conversations that they have around making our system much better.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
